Oncolytics Biotech Inc.
ONCYNext catalyst
Pelareorep
Anal Cancer Metastatic
Get an email about ONCY's next catalysts
Track Oncolytics Biotech (ONCY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (conference, Phase 2 readout).See the timeline
3 upcoming, 1 past
Conference Presentation - pelareorep
For relapsed/refractory multiple myeloma. Oncolytics announced translational single-cell sequencing data from a Phase 1b/2 trial of pelareorep combined with bortezomib, dexamethasone, and pembrolizumab in heavily pretreated relapsed/refractory multiple myeloma patients, showing immune activation and tumor microenvironment remodeling. The data will be presented as a poster at the ASH Annual Meeting on December 12, 2026.
SourcePelareorep Phase 2 Est. Readout (GOBLET)
Primary completion for Pelareorep trial (NCT07280377) in Anal Cancer Metastatic
SourcePelareorep Phase 2 Est. Readout
Estimated primary completion for Pelareorep trial (NCT07446322) in Ras-mutated Metastatic Colorectal Cancer. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Oncolytics Biotech Inc. is a biotech company headquartered in San Diego, California, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.
WebsiteREOLYSIN
Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
REOLYSIN®
Carcinoma, Non-small Cell Lung
Docetaxel, Reolysin and Prednisone
Prostate Cancer
Pemetrexed and Reolysin (and safety run-in)
Non Small Cell Lung Cancer
Trifluridine Tipiracil
Anal Cancer Metastatic
Folfox plus Bevacizumab and reolysin
Colorectal Cancer
mFOLFIRINOX Treatment Regimen
Anal Cancer Metastatic
Docetaxel and Reolysin
Non Small Cell Lung Cancer
Pelareorep
Anal Cancer Metastatic
Folfox plus Bevacizumab
Colorectal Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
REOLYSIN | Phase 3 | Metastatic or Recurrent Squamous Cell Carcinoma of the Lung | - | - |
REOLYSIN® | Phase 2 | Carcinoma, Non-small Cell Lung | - | - |
Docetaxel, Reolysin and Prednisone | Phase 2 | Prostate Cancer | - | - |
Pemetrexed and Reolysin (and safety run-in) | Phase 2 | Non Small Cell Lung Cancer | - | - |
Trifluridine Tipiracil | Phase 2 | Anal Cancer Metastatic | - | - |
Folfox plus Bevacizumab and reolysin | Phase 2 | Colorectal Cancer | - | - |
mFOLFIRINOX Treatment Regimen | Phase 2 | Anal Cancer Metastatic | - | - |
Docetaxel and Reolysin | Phase 2 | Non Small Cell Lung Cancer | - | - |
Pelareorep | Phase 2 | Anal Cancer Metastatic | - | - |
Folfox plus Bevacizumab | Phase 2 | Colorectal Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Oncolytics Biotech Inc.'s drug pipeline?→
CatalystAlert tracks 10 drug candidates in Oncolytics Biotech Inc.'s (ONCY) pipeline across Phase 3, Phase 2. Its lead program is REOLYSIN (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Oncolytics Biotech Inc.'s next FDA catalyst?→
Oncolytics Biotech Inc.'s (ONCY) next tracked catalyst is a Phase 2 readout expected Q3 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ONCY biotech catalysts?→
Add ONCY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Oncolytics Biotech Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
